Genotyping the tumour samples would assist in determining whether a polymorphism or variant in TET2 is the cause of downregulated TET2 levels, thereby further supporting previous findings regarding TET2 as a potential marker and driver of malignancy in NHL. The gene discussed is TET2; the disease is non-Hodgkin lymphoma.